Abstract
ObjectivesTo compare the extent of clinical benefit and cost effectiveness of olaparib in ovarian cancer compared to breast, pancreatic, and prostate cancer.MethodsData were extracted from FDA labels for olaparib. We...
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
